WO1992019749A1 - Targeted delivery of genes encoding cell surface receptors - Google Patents
Targeted delivery of genes encoding cell surface receptors Download PDFInfo
- Publication number
- WO1992019749A1 WO1992019749A1 PCT/US1992/003639 US9203639W WO9219749A1 WO 1992019749 A1 WO1992019749 A1 WO 1992019749A1 US 9203639 W US9203639 W US 9203639W WO 9219749 A1 WO9219749 A1 WO 9219749A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- cell
- molecular complex
- binding agent
- receptor
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 117
- 108010001857 Cell Surface Receptors Proteins 0.000 title claims abstract description 25
- 102000006240 membrane receptors Human genes 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract description 72
- 239000011230 binding agent Substances 0.000 claims abstract description 39
- 102000000844 Cell Surface Receptors Human genes 0.000 claims abstract description 24
- 102000005962 receptors Human genes 0.000 claims abstract description 23
- 108020003175 receptors Proteins 0.000 claims abstract description 23
- 239000003446 ligand Substances 0.000 claims abstract description 21
- 210000003494 hepatocyte Anatomy 0.000 claims abstract description 20
- 230000009870 specific binding Effects 0.000 claims abstract description 18
- 238000001727 in vivo Methods 0.000 claims abstract description 15
- 230000014509 gene expression Effects 0.000 claims abstract description 14
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 claims abstract description 9
- 108010006523 asialoglycoprotein receptor Proteins 0.000 claims abstract description 9
- 230000008685 targeting Effects 0.000 claims abstract description 9
- 230000003834 intracellular effect Effects 0.000 claims abstract description 7
- 230000012202 endocytosis Effects 0.000 claims abstract description 6
- 108020004414 DNA Proteins 0.000 claims description 35
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 21
- 239000013612 plasmid Substances 0.000 claims description 17
- 108010039918 Polylysine Proteins 0.000 claims description 11
- 229920000656 polylysine Polymers 0.000 claims description 11
- 108010002913 Asialoglycoproteins Proteins 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 6
- 108091092724 Noncoding DNA Proteins 0.000 claims description 3
- 108020005202 Viral DNA Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 abstract description 10
- 238000001415 gene therapy Methods 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 239000012528 membrane Substances 0.000 abstract description 4
- 238000003780 insertion Methods 0.000 abstract description 3
- 230000037431 insertion Effects 0.000 abstract description 3
- 210000000170 cell membrane Anatomy 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 239000012530 fluid Substances 0.000 abstract description 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 34
- 241000283973 Oryctolagus cuniculus Species 0.000 description 21
- 239000012634 fragment Substances 0.000 description 21
- 210000004185 liver Anatomy 0.000 description 20
- 108010001831 LDL receptors Proteins 0.000 description 16
- 108010084541 asialoorosomucoid Proteins 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 8
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 8
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 102000006382 Ribonucleases Human genes 0.000 description 6
- 108010083644 Ribonucleases Proteins 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 208000028782 Hereditary disease Diseases 0.000 description 5
- 101000930477 Mus musculus Albumin Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 208000024556 Mendelian disease Diseases 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 108020004518 RNA Probes Proteins 0.000 description 3
- 239000003391 RNA probe Substances 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 210000001865 kupffer cell Anatomy 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 101000930457 Rattus norvegicus Albumin Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010061952 Orosomucoid Proteins 0.000 description 1
- 102000012404 Orosomucoid Human genes 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 108010044715 asialofetuin Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 239000002801 charged material Substances 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001159 endocytotic effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000009716 hepatic expression Effects 0.000 description 1
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940070353 protamines Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- Familial hypercholesterolemia is an inherited disease in humans, caused by a deficiency of low-density lipoprotein (LDL) receptors. FH is associated with hypercholesterolemia and premature development of coronary heart disease. J.L. Goldstein and M.S. Brown in The Metabolic Basis of Inherited Disease (C.R. Scriver, A.L. Beaudet, W.S. Sly and D. Valle eds.) McGraw-Hill, New York, Sixth edition, pp. 1215-1250. Current therapies for FH primarily attempt to decrease serum LDL cholesterol by increasing hepatic expression of the LDL receptor. J.L. Goldstein and M.S.
- ⁇ s vivo gene therapy in the liver may be limited, in part, by the morbidity of the invasive procedures used to harvest and transplant hepatocytes. Delivery of genes to hepatocytes and other cells in vivo would be of value in treating FH and other acquired and inherited diseases.
- This invention pertains to a soluble molecular complex for targeting a gene encoding a cell surface receptor, such as the LDL receptor, to a specific cell in vivo and obtaining expression of the gene by the targeted cell.
- the molecular complex comprises an expressible gene encoding a desired cell surface receptor complexed with a carrier which is a conjugate of a cell-specific binding agent and a gene-binding agent.
- the cell-specific binding agent is specific for a cellular surface structure, typically a receptor, which mediates internalization of bound ligands by endocytosis, such as the asialoglycoprotein receptor of hepatocytes.
- the cell-specific binding agent can be a natural or synthetic ligand (for example, a protein, poly- peptide, glycoprotein, etc.) or it can be an antibody, or an analogue thereof, which specifically binds a cellular surface structure which then mediates internalization of the bound complex.
- the gene-binding component of the conjugate is a compound such as a polycation which stably complexes the gene under extracellular conditions and releases the gene under intracellular conditions so that it can function within the cell.
- the complex of the gene and the carrier is stable and soluble in physiological fluids. It can be administered in vivo where it is selectively taken up by the target cell via the surface-structure- mediated endocytotic pathway.
- the incorporated gene is expressed and the gene-encoded receptor is processed and inserted into the cell membrane of the transfected cell.
- the soluble molecular complex of this invention can be used to specifically transfect cells in vivo to provide for expression of a desired cell surface receptor. This selective transfection is useful for gene therapy and in other applications which require selective genetic alteration of cells to produce a desired surface receptor.
- a normal gene can be targeted to a specific cell to correct or alleviate an inherited or acquired abnormality involving a cell surface receptor, such as familial hypercholesterolemia, caused in part by a defect in the LDL receptor gene.
- FIG. 1 shows the structure of the LDL receptor expression vector p9-12alb(h)LDLR.
- the vector contains the structural gene for human LDL receptor driven by rat albumin promoter and mouse albumin enhancer sequences.
- Figure 2 shows that the LDLR-complex is primarily targeted to the liver. 125 I uptake by various organs was determined following injection of radiolabeled LDLR-complex.
- Figure 3 shows the cellular distribution of the
- LDLR-complex which indicates the complex is predominantly taken up by hepatocytes.
- Figure 4A shows DNA blot hybridization analysis of total cellular DNA which indicates that the LDLR-complex remains intact extracellularly and delivers functional DNA.
- Figure 4B shows RNase protection analysis which confirms the presence of recombinant human LDL receptor transcripts in the liver.
- Figure 5 shows the results of a two treatment crossover study measuring total serum cholesterol to confirm the presence of human LDL receptor.
- a soluble, targetable molecular complex is used to selectively deliver a gene encoding a cell surface receptor to a target cell or tissue n vivo.
- the molecular complex comprises the receptor-encoding gene to be delivered complexed to a carrier made up of a binding agent specific for the target cell and a gene-binding agent.
- the complex is selectively taken up by the target cell and the gene-encoded receptor is expressed, processed, and inserted into the cellular membrane.
- the gene encodes the desired cell surface receptor.
- the gene comprises a structural gene encoding the receptor in a form suitable for processing by the target cell.
- the gene encodes appropriate signal sequences which direct processing and membrane insertion of the receptor.
- the signal sequence may be the natural sequence of the receptor or exogenous sequences.
- the structural gene is linked to appropriate genetic regulatory elements required for expression of the gene-encoded receptor by the target cell. These include a promoter and optionally an enhancer element operable in the target cell.
- the gene can be contained in an expression vector such.as a plasmid or a transposable genetic element along with the genetic regulatory elements necessary for expression of the gene and production of the gene-encoded product.
- the carrier component of the complex is a conjugate of a cell-specific binding agent and a gene-binding agent.
- the cell-specific binding agent specifically binds a cellular surface structure which mediates internalization by, for example, the process of endocytosis.
- the surface structure can be a protein, polypeptide, carbohydrate, lipid or combination thereof. It is typically a surface receptor which mediates endocytosis of a ligand.
- the binding agent can be a natural or synthetic ligand which binds the receptor.
- the ligand can be a protein, polypeptide, glycoprotein or glycopeptide which has functional groups that are exposed sufficiently to be recognized by the cell surface structure.
- the binding agent can also be an antibody, or an analogue of an antibody such as a single chain antibody which binds the cell surface structure.
- Ligands useful in forming the carrier will vary according to the particular cell to be targeted.
- glycoproteins having exposed terminal carbohydrate groups such as asialoglyco- protein (galactose-terminal) can be used, although other ligands such as polypeptide hormones may also be employed.
- asialoglycoproteins include asialoorosomucoid, asialofetuin and desialylated vesicular stomatitis virus.
- Such ligands can be formed by chemical or enzymatic desialylation of glycoproteins that possess terminal sialic acid and penultimate galactose residues.
- asialoglycoprotein ligands can be formed by coupling galactose terminal carbohydrates such as lactose or arabinogalactan to non-galactose bearing proteins by reductive lactosamination.
- galactose terminal carbohydrates such as lactose or arabinogalactan
- non-galactose bearing proteins such as lactose or arabinogalactan
- other types of ligands can be used, such as mannose for macrophages, mannose-6- phosphate glycoproteins for fibroblasts, intrinsic factor-vitamin B12 for enterocytes and insulin for fat cells.
- the cell-specific binding agent can be a receptor or receptor-like molecule, such as an antibody which binds a ligand (e.g., antigen) on the cell surface.
- ligand e.g., antigen
- the gene-binding agent complexes the gene to be delivered. Complexation with the gene must be sufficiently stable vivo to prevent significant uncoupling of the gene extracellularly prior to internalization by the target cell. However, the complex is cleavable under appropriate conditions within the cell so that the gene is released in functional form. For example, the complex can be labile in the acidic and enzyme rich environment of lysosomes. A noncovalent bond based on electrostatic attraction between the gene-binding agent and the gene provides extracellular stability and is releasable under intracellular conditions.
- Preferred gene-binding agents are polycations that bind negatively charged polynucleotides.
- Suitable polycations are polylysine, polyarginine, polyornithine, basic proteins such as histones, avidin, protamines and the like.
- a preferred polycation is polylysine.
- noncovalent bonds that can be used to releasably link the expressible gene include hydrogen bonding, hydrophobic bonding, electrostatic bonding alone or in combination such as, anti-polynucleotide antibodies bound to polynucleotide, and strepavidin or avidin binding to polynucleotide containing biotinylated nucleotides.
- the carrier can be formed by chemically linking the cell-specific binding agent and the gene-binding agent.
- the linkage is typically covalent.
- a preferred linkage is a peptide bond. This can be formed with a water soluble carbodiimide as described by G. Jung e_t .al. Biochem. Biophvs. Res. Commun. l£JL:599-606 (1981).
- An alternative linkage is a disulfide bond.
- the linkage reaction can be optimized for the particular cell-specific binding agent and gene-binding agent used to form the carrier. Reaction conditions can be designed to maximize linkage formation but to minimize the formation of aggregates of the carrier components. The optimal ratio of cell-specific binding agent to gene-binding agent can be determined empirically.
- the molar ratio of the components will vary with the size of the polycation and the size of the gene. In general, this ratio ranges from about 10:1 to 1:1, preferably about 5:1. Uncoupled components and aggregates can be separated from the carrier by molecular sieve chromatography.
- the gene encoding the desired cell surface receptor can be complexed to the carrier by a stepwise dialysis procedure. In a preferred method, for use with carriers made of polycations such as polylysine, the dialysis procedure begins with a 2M NaCl dialyzate and ends with a 0.15M NaCl solution. The gradually decreasing NaCl concentration results in binding of the DNA to the carrier.
- the molecular complex can contain more than one copy of the same gene or one or more different genes.
- the ratio of polynucleotide to the carrier is from about 1:5 to 5:1, preferably about 1:2.
- the molecular complex of this invention can be administered parenterally. Preferably, it is injected intravenously.
- the complex is administered in solution in a physiologically acceptable vehicle.
- Cells can be transfected in vivo for transient expression and production of the gene product. For prolonged expression and production, the gene can be administered repeatedly. Alternatively, the transfected target cell can be stimulated to replicate by surgical or pharmacological means to prolong expression of the incorporated gene. See, for example, U.S. Patent Application Serial No. 588,013, filed September 25, 1990, the teachings of which are incorporated by reference herein.
- the method of this invention can be used in gene therapy to selectively deliver a gene encoding a cell surface receptor to a target cell in vivo for expression.
- a gene encoding a desired cell surface receptor can be targeted to a cell which normally expresses the receptor but which lacks the capacity to produce the receptor or produces an insuffient amount of the receptor because of an acquired or inherited defect.
- a normal gene can be targeted to a specific cell to correct or alleviate a metabolic or genetic abnormality caused by an inherited or acquired defect in a corresponding endogenous gene encoding a cell surface receptor.
- the gene can be delivered to a cell which does not normally express the surface receptor to confer a new function upon the cell.
- the cell surface receptor can be a receptor for a natural ligand such as a metabolite, a hormone, a growth factor, a cytokine, an ion (ion transport protein), a virus, or a protozoan. It can also be a receptor that mediates cell-cell interaction.
- a natural ligand such as a metabolite, a hormone, a growth factor, a cytokine, an ion (ion transport protein), a virus, or a protozoan.
- It can also be a receptor that mediates cell-cell interaction.
- In vivo gene transfer has several potential advantages over organ/cell transplantation in the treatment of metabolic diseases of the liver.
- One advantage is that the therapeutic gene is expressed in situ in a cell and organ that has not been manipulated ⁇ x vivo.
- the capacity of this approach to reconstitute hepatic gene expression is theoretically greater than the capacity of cellular therapies which are usually limited by the number of cells that will engraft
- Familial hypercholesterolemia is an inherited disease in humans caused by a deficiency in the receptor for LDL.
- the gene encoding the human LDL receptor is complexed to a conjugate of an asialoglycoprotein and a polycation.
- the resulting soluble complex is administered parenterally to the individual afflicted with the LDL receptor deficiency in amounts sufficient to selectively transfect cells and to provide sufficient production of the cell surface receptor to attain normal levels of serum cholesterol.
- DNA encoding human LDL receptor is described in U.S. Patent 4,745,060, the contents of which are incorporated herein by reference.
- asialoglycoprotein-polycation conjugate consisting of asialoorosomucoid (ASOR) coupled to polylysine, was used to form a soluble DNA complex capable of specifically targeting hepatocytes via asialoglycoprotein receptors present on these cells.
- the DNA comprised a plasmid, p9-12alb(h)LDLR, containing the structural gene for the human LDL receptor driven by rat albumin promoter and mouse albumin enhancer elements.
- WHHL Watanabe Heritable Hyperlipidemic
- NZW Wild-type New Zealand White
- Animals were maintained on a Purina laboratory rabbit chow and weighed 2-3 kg at the time of experi ⁇ mentation. Phlebotomies were performed at 3 to 4 PM. Experiments were conducted in accordance with the guidelines of the Committee on Use and Care of Animals from the University of Michigan and Albert Einstein College of Medicine. Construction of DNA Vector
- a vector capable of expressing normal human LDL receptor was constructed (p9-12alb(h)LDLR) for in vivo gene transfer experiments in WHHL rabbits ( Figure 1) .
- Transcriptional elements from the mouse albumin gene were used to drive expression of a full-length cDNA for the human LDL receptor.
- Fragment A is an Xbal to Bglll fragment (3.6 kb) of plasmid MTEV.JT (provided by J.
- Trill which contains several functional elements including a 231 base pair (bp) fragment of genomic DNA spanning the polyadenyl- ation signal of the bovine growth hormone gene, ⁇ -lactamase and the prokaryotic origin of replication from PUC 19, and a eukaryotic transcriptional unit expressing xanthine-guanine phosphoribosyltransferase (XGPRT) ; Fragment B includes sequences spanning an enhancer located 5' to the mouse albumin gene (-12 to -9 kb) excised on an Eco RV to Bglll fragment and fused in reverse orientation to sequences spanning the mouse albumin promoter (-282 to +21). L.E. Babiss e_£ ⁇ l- Proc. Natl.
- the 5' end of the chimeric fragment is formed by the natural Bglll site of the albumin enhancer (-9 kb) while the 3' end of the fragment contains a synthetic Sail site attached to position +22 of the albumin promoter sequence; and Fragment C is a Sail to Xbal fragment (3.0 kb) derived from a previously published retroviral vector LTR-LDLR. J.M. Wilson st al. Proc. Natl. Acad. Sci. ££:4421 (1988).
- the LTR-LDLR vector includes the entire cDNA for human LDL receptor (2.6 kb) along with 430 bp of additional 3' sequence derived from the retroviral genome (nucleotides 7816 to 8113 of the Moloney murine leukemia virus genome; see C. Van Beveren e_£ Si. in RNA Tumor Viruses (R. Weiss, N. Teich, H. Varmus, and J. Coffin eds.) Cold Spring Harbor Lab., Cold Spring Harbor N.Y., 2nd Ed., pp. 766-783 (1985) for numbering).
- the 5' end of the LDL receptor cDNA was converted to a Sail site in preparation for this construction.
- LDL receptor sequences in p9-12alb(h)LDLR were replaced with sequences encoding the prokaryotic gene chloroamphenicol acetyltransferase (CAT) to generate a vector called p9-12albCAT (provided by S. Camper).
- CAT chloroamphenicol acetyltransferase
- This vector was used as a negative control in metabolic experiments based on the assumption that CAT expression does not specifically affect intracellular hepatic cholesterol metabolism.
- DNA/protein complexes were synthesized with either p9-2alb(h)LDLR (LDLR-complex) or p9-12albCAT (CAT-complex) (See below) . Construction of Gene Carrier and Gene Carrier Complexes
- a high affinity ligand for the asialoglycoprotein receptor, asialoorosomucoid (ASOR) was covalently attached to polylysine to produce a gene carrier useful in the study of the organ and cellular distribution of DNA/protein complex uptake in vivo.
- ASOR asialoorosomucoid
- LDLR- complexes were synthesized with ASOR.
- the gene carriers were prepared as described previously. G.Y. Wu fit al. J. Biol. Chem. 2£4.:16985 (1989).
- LDLR-Complex Targeting of the LDLR-Complex to the Liver Animals were anesthetized with ketamine HC1 (40 mg/kg) and xylazine (10 mg/kg) in preparation for the experiment. Radiolabeled LDLR-complexes were injected into the marginal ear vein of New Zealand White (NZW) or WHHL adult rabbits (2 to 3 kg) which were euthenized and exanguinated 10 minutes later. Individual organs were harvested and analyzed for incorporation of radioactivity (Figure 2) . DNA/protein complex was rapidly cleared from the plasma and primarily taken up by the liver (85% of total recovered radioactivity) after 10 minutes.
- NZW New Zealand White
- WHHL adult rabbits 2 to 3 kg
- Organ distribution of uptake was shown to be independent of the phenotype of the recipient animal (NZW, heterozygous WHHL, and homozygous WHHL) and the dose of injected complex (from 0.17 mg to 4 mg of DNA in a complex) .
- B Tracer quantities of ASOR labeled complex into a WHHL rabbit (heterozygous).
- LDLR-Complex Although the hepatocyte is the predominant cell type in the liver and the likely target for gene transfer, nonparenchymal cells of the liver, such as endothelial cells and kupffer cells, could potential ⁇ ly serve as alternative targets.
- rabbits were injected with radiolabeled LDLR-complex as described above. Ten minutes after injection, the portal vein was cannulated, and the liver was perfused with 154 mM NaCl for 5 minutes followed by Karnovsky's fixative for 10 minutes. R. St. Hilaire fit al * Proc. Natl. Acad. Sci. 80:3797 (1983).
- Random blocks of liver were cut on ice to 2 - 5 mm ⁇ cubes and were kept in fresh fixative for 2 hours prior to transfer to a 0.2 M sodium bicarbonate, pH 7.4, overnight at room temperature. Blocks were embedded in Epox 812 (W.O. Dobbins III in Diagnostic Electron Microscopy (B.F. Trump and R.T. Jones eds.) Wiley, New York, Vol. 1, pp. 253-339) and 1 ⁇ m sections were cut and mounted on polylysine-coated slides which were dipped in NTB3 nuclear emulsion.
- Panel B Analysis of liver tissue from a WHHL rabbit that was injected with saline. In each case, magnification is 400x. Radioactive signal, detected as silver grains, was 100-fold over that observed in unlabeled liver tissue ( Figure 3). The majority of this signal (>90%) was seen as discrete grains located over hepatocytes ( Figure 3A) .
- Radioactive signal was infrequently seen over kupffer cells as aggregates or discrete grains (Figure 3A) .
- This nonparenchymal cell uptake may represent larger forms of the DNA/protein complex that have been phagocytized by kupffer cells.
- the intracellular fate of the recombinant gene was studied in WHHL rabbits after administration of unlabeled LDLR-complex. Animals were euthanized 10 minutes, 4 hours, and 24 hours after in vivo gene transfer and liver tissue was characterized with respect to the abundance and structural integrity of the recombinant gene as well as the level of recombinant derived RNA.
- Samples include control WHHL DNA (10 ⁇ g) mixed with the equivalent of 100 copies/cell (750 pg; lane *100c'), 10 copies/cell (75 pg; lane '10c'), and 1 copy/cell (7.5 pg; lane , lc') of p9-12alb(h)LDLR plasmid DNA. Additional DNA samples (10 ⁇ g) are from WHHL rabbits injected with LDLR-complex and harvested 10 minutes (lane '10 min'), 4 hours (lane '4 hr"), and 24 hours (lane *24 hr') later. The filter was exposed to film for 45 minutes (top panel) and 24 hours (bottom panel) . Molecular weight markers are noted in base pairs along the left border.
- liver tissue harvested 10 minutes after injection of the LDLR-complex demonstrated very high levels of the intact fragment along with some partially degraded plasmid DNA; comparison to plasmid controls indicated that this tissue contained approximately 5,000 to 10,000 copies of plasmid per cell.
- This estimate of gene targeting is in agreement with the level of gene delivery to the liver expected from the amount of DNA injected (this estimate is based on the injection of 4 mg of plasmid (10 kb in size) into a 2-3 kg rabbit that has 2 - 4 x 10 10 hepatocytes).
- Analysis of livers harvested at later time points revealed ongoing degradation of the plasmid and a progressive decline in the abundance of the intact plasmid from 100 copies/cell at 4 hours to 1 copy/cell at 24 hours.
- Liver tissues were analyzed for the presence and abundance of recombinant human LDL receptor transcripts using a quantitative RNase protection assay. J.M. Wilson f it al. Proc. Natl. Acad. Sci.
- RNA derived from the p9-12alb(h)LDLR vector was detected with an antisense RNA probe that is synthesized from the previously described vector 3Z-env. J.M. Wilson fit al. Proc. Natl. Acad. Sci. £7:8437 (1990).
- This RNA probe is complementary to vector specific sequences in the 3* untranslated region of the recombinant transcript. RNase protection of the resulting duplex produces a protected fragment of 172 bp ( Figure 4B) .
- Antisense RNA that specifically detects endogenous WHHL LDL receptor RNA was used as an internal control in each assay.
- the transcription vector used to synthesize the RNA probe (3Z-WLDLR) was constructed in the following manner.
- the Nar I site was converted to a Hind III site with synthetic linkers and the revised fragment was ligated with the Hind III to Sma I backbone fragment of pGEM3Zf(+) (Promega).
- Endogenous WHHL LDL receptor RNA is detected with the 3Z-wLDLR probe in RNase protection assays as a 80 bp band.
- RNA probes were gel purified prior to use. M.H. Finer in Methods in Molecular Biology. Vol. 7: Gene Transfer and Expression Techniques (E.J. Murray and J.M. Walker eds.) The Humana Press Inc., Clifton, NJ, pp. ⁇ _i5 (1990).
- Total cellular RNA prepared from liver was hybridized with equal quantities of 3Z-env and 3Z-wLDLR probe (5x10-5 cpm of each probe per assay) and analyzed for protection to digestion with RNase A. J.M. Wilson fit al. Proc. Natl. Acad. Sci. £7:8437 (1990). Samples were electrophoresed through a 6% polyacrylamide/urea denaturing gel; a representative autoradiograph is presented. Radioactivity in the resulting bands was quantified with a Beta Scope 630 (Betagen, Waltham MA) . The following samples were analyzed.
- Lane '3T3' contains RNA (100 ⁇ g) from a control WHHL supplemented with RNA (100 ng) from a fibroblast cell line (NIH3T3) that produces recombinant LDL receptor transcripts containing sequences complementary to the 3z-env probe.
- RNA 100 ⁇ g
- WHHL rabbit a untransfected WHHL rabbit
- WHHL rabbits injected with LDLR-complex and harvested 10 minutes (lane "10 min*), 4 hours (lane '4 hr'), and 24 hours (lanes 24A and 24B, representing two different animals) .
- the undigested probes (2 x 10 3 cpm/lane) were electrophoresed in lanes '3Z-env' and '3Z-WLDLR'.
- Molecular weight markers ⁇ ATP labeled pBr322/X Hae III fragments
- their corresponding sizes in base pairs are presented in the far right lane.
- the closed arrow indicates the location of the 3Z-env protected band while the open arrow indicates the location of the 3Z-wLDLR protected band.
- Endogenous LDL receptor RNA was specifically detected in RNase protection assays as a 80 bp protected fragment; no hybridization to human LDL receptor RNA was noted. The intensity of the resulting bands is proportional to the amount of RNA used in the initial hybridization suggesting that this assay can be used to quantify recombinant and endogenous transcripts.
- Recombinant RNA was not detected in mock-transfected liver or in liver harvested 10 minutes after administration of the LDLR-complex. Livers removed 4 hours and 24 hours after in vivo gene transfer contained significant levels of the recombinant transcript. Quantitative analysis of the assay was used to estimate the abundance of vector- derived RNA relative to the endogenous LDL receptor transcript; levels of the recombinant LDL receptor transcript rose from undetectable at 10 minutes ( ⁇ 0.05% of endogenous), to 1.3% of endogenous at 4 hours, and 4.0% (24A) and 2.0% (24B) of endogenous at 24 hours.
- WHHL rabbits were injected with LDLR-complex or CAT-complex and analyzed for changes in total serum cholesterol.
- Six WHHL rabbits were entered into a protocol that involved a two treatment (injection of p9-12alb(h)LDLR (LDLR-complex) or p9-12albCAT (CAT-complex) plasmid; 5.0 g of total DNA in a complex/dose), two period, cross-over design, with repeated measurements of total serum cholesterol within each period (Figure 5).
- the DNA/protein complex was injected into the marginal ear vein over a 2 minute time period.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Molecular complexes for targeting a gene encoding a cell surface receptor to a specific cell in vivo and obtaining expression of the gene and insertion of the gene-encoded receptor in the cell membrane. An expressible gene encoding a desired cell surface receptor is complexed with a carrier of a cell-specific binding agent and a gene-binding agent. The cell-specific binding agent is specific for a cellular surface structure which mediates internalization of ligands by endocytosis. An example is the asialoglycoprotein receptor of hepatocytes. The gene-binding agent is a compound such as a polycation which stably complexes the gene under extracellular conditions and releases the gene under intracellular conditions so that it can function within a cell. The molecular complex is stable and soluble in physiological fluids and can be used in gene therapy to selectively transfect cells in vivo to provide for production, membrane insertion and function of a cellular surface receptor.
Description
TARGETED DELIVERY OF GENES ENCODING CELL SURFACE RECEPTORS
Background of the Invention
Familial hypercholesterolemia (FH) is an inherited disease in humans, caused by a deficiency of low-density lipoprotein (LDL) receptors. FH is associated with hypercholesterolemia and premature development of coronary heart disease. J.L. Goldstein and M.S. Brown in The Metabolic Basis of Inherited Disease (C.R. Scriver, A.L. Beaudet, W.S. Sly and D. Valle eds.) McGraw-Hill, New York, Sixth edition, pp. 1215-1250. Current therapies for FH primarily attempt to decrease serum LDL cholesterol by increasing hepatic expression of the LDL receptor. J.L. Goldstein and M.S. Brown in The Metabolic Basis of Inherited Disease supra. This has been accomplished in homozygous patients by orthotopic liver transplantion from donors who express normal levels of LDL receptor. Short term metabolic efficacy in the animal model for FH, the Watanabe Heritable Hyperlipidemic rabbit (WHHL) , has been demonstrated by transplanting allogenic wild-type hepatocytes or WHHL hepatocytes genetically
corrected ≤x vivo with recombinant retroviruses. J.M. Wilson e± si. Proc. Natl. Acad. Sci. 15.:4421 (1988) and J.M. Wilson ej£ aJL. Proc. Natl. Acad. Sci. £7:8437 (1990). The clinical utility of ≤s vivo gene therapy in the liver may be limited, in part, by the morbidity of the invasive procedures used to harvest and transplant hepatocytes. Delivery of genes to hepatocytes and other cells in vivo would be of value in treating FH and other acquired and inherited diseases.
Summary of the Invention
This invention pertains to a soluble molecular complex for targeting a gene encoding a cell surface receptor, such as the LDL receptor, to a specific cell in vivo and obtaining expression of the gene by the targeted cell. The molecular complex comprises an expressible gene encoding a desired cell surface receptor complexed with a carrier which is a conjugate of a cell-specific binding agent and a gene-binding agent. The cell-specific binding agent is specific for a cellular surface structure, typically a receptor, which mediates internalization of bound ligands by endocytosis, such as the asialoglycoprotein receptor of hepatocytes. The cell-specific binding agent can be a natural or synthetic ligand (for example, a protein, poly- peptide, glycoprotein, etc.) or it can be an antibody, or an analogue thereof, which specifically binds a cellular surface structure which then mediates internalization of the bound complex. The gene-binding component of the conjugate is a compound
such as a polycation which stably complexes the gene under extracellular conditions and releases the gene under intracellular conditions so that it can function within the cell. The complex of the gene and the carrier is stable and soluble in physiological fluids. It can be administered in vivo where it is selectively taken up by the target cell via the surface-structure- mediated endocytotic pathway. The incorporated gene is expressed and the gene-encoded receptor is processed and inserted into the cell membrane of the transfected cell.
The soluble molecular complex of this invention can be used to specifically transfect cells in vivo to provide for expression of a desired cell surface receptor. This selective transfection is useful for gene therapy and in other applications which require selective genetic alteration of cells to produce a desired surface receptor. In gene therapy, a normal gene can be targeted to a specific cell to correct or alleviate an inherited or acquired abnormality involving a cell surface receptor, such as familial hypercholesterolemia, caused in part by a defect in the LDL receptor gene.
Brief Description of The Figures
Figure 1 shows the structure of the LDL receptor expression vector p9-12alb(h)LDLR. The vector contains the structural gene for human LDL receptor driven by rat albumin promoter and mouse albumin enhancer sequences.
Figure 2 shows that the LDLR-complex is primarily targeted to the liver. 125I uptake by various organs was determined following injection of radiolabeled LDLR-complex. Figure 3 shows the cellular distribution of the
LDLR-complex which indicates the complex is predominantly taken up by hepatocytes.
Figure 4A shows DNA blot hybridization analysis of total cellular DNA which indicates that the LDLR-complex remains intact extracellularly and delivers functional DNA.
Figure 4B shows RNase protection analysis which confirms the presence of recombinant human LDL receptor transcripts in the liver. Figure 5 shows the results of a two treatment crossover study measuring total serum cholesterol to confirm the presence of human LDL receptor.
Detailed Description of the Invention
A soluble, targetable molecular complex is used to selectively deliver a gene encoding a cell surface receptor to a target cell or tissue n vivo. The molecular complex comprises the receptor-encoding gene to be delivered complexed to a carrier made up of a binding agent specific for the target cell and a gene-binding agent. The complex is selectively taken up by the target cell and the gene-encoded receptor is expressed, processed, and inserted into the cellular membrane.
The gene, generally in the form of DNA, encodes the desired cell surface receptor. Typically, the gene comprises a structural gene encoding the receptor in a form suitable for processing by the
target cell. For example, the gene encodes appropriate signal sequences which direct processing and membrane insertion of the receptor. The signal sequence may be the natural sequence of the receptor or exogenous sequences. The structural gene is linked to appropriate genetic regulatory elements required for expression of the gene-encoded receptor by the target cell. These include a promoter and optionally an enhancer element operable in the target cell. The gene can be contained in an expression vector such.as a plasmid or a transposable genetic element along with the genetic regulatory elements necessary for expression of the gene and production of the gene-encoded product. The carrier component of the complex is a conjugate of a cell-specific binding agent and a gene-binding agent. The cell-specific binding agent specifically binds a cellular surface structure which mediates internalization by, for example, the process of endocytosis. The surface structure can be a protein, polypeptide, carbohydrate, lipid or combination thereof. It is typically a surface receptor which mediates endocytosis of a ligand. Thus, the binding agent can be a natural or synthetic ligand which binds the receptor. The ligand can be a protein, polypeptide, glycoprotein or glycopeptide which has functional groups that are exposed sufficiently to be recognized by the cell surface structure. It can also be a component of a biological organism such as a virus, cells (e.g., mammalian, bacterial, protozoan) or artificial carriers such as liposomes.
The binding agent can also be an antibody, or an analogue of an antibody such as a single chain antibody which binds the cell surface structure.
Ligands useful in forming the carrier will vary according to the particular cell to be targeted. For targeting hepatocytes, glycoproteins having exposed terminal carbohydrate groups such as asialoglyco- protein (galactose-terminal) can be used, although other ligands such as polypeptide hormones may also be employed. Examples of asialoglycoproteins include asialoorosomucoid, asialofetuin and desialylated vesicular stomatitis virus. Such ligands can be formed by chemical or enzymatic desialylation of glycoproteins that possess terminal sialic acid and penultimate galactose residues. Alternatively, asialoglycoprotein ligands can be formed by coupling galactose terminal carbohydrates such as lactose or arabinogalactan to non-galactose bearing proteins by reductive lactosamination. For targeting the molecular complex to other cell surface receptors, other types of ligands can be used, such as mannose for macrophages, mannose-6- phosphate glycoproteins for fibroblasts, intrinsic factor-vitamin B12 for enterocytes and insulin for fat cells. Alternatively, the cell-specific binding agent can be a receptor or receptor-like molecule, such as an antibody which binds a ligand (e.g., antigen) on the cell surface. Such antibodies can be produced by standard procedures. The gene-binding agent complexes the gene to be delivered. Complexation with the gene must be sufficiently stable vivo to prevent significant uncoupling of the gene extracellularly prior to
internalization by the target cell. However, the complex is cleavable under appropriate conditions within the cell so that the gene is released in functional form. For example, the complex can be labile in the acidic and enzyme rich environment of lysosomes. A noncovalent bond based on electrostatic attraction between the gene-binding agent and the gene provides extracellular stability and is releasable under intracellular conditions. Preferred gene-binding agents are polycations that bind negatively charged polynucleotides. These positively charged materials can bind noncovalently with the gene to form a soluble, targetable molecular complex which is stable extracellularly but releasable intracellularly. Suitable polycations are polylysine, polyarginine, polyornithine, basic proteins such as histones, avidin, protamines and the like. A preferred polycation is polylysine. Other noncovalent bonds that can be used to releasably link the expressible gene include hydrogen bonding, hydrophobic bonding, electrostatic bonding alone or in combination such as, anti-polynucleotide antibodies bound to polynucleotide, and strepavidin or avidin binding to polynucleotide containing biotinylated nucleotides.
The carrier can be formed by chemically linking the cell-specific binding agent and the gene-binding agent. The linkage is typically covalent. A preferred linkage is a peptide bond. This can be formed with a water soluble carbodiimide as described by G. Jung e_t .al. Biochem. Biophvs. Res. Commun. l£JL:599-606 (1981). An alternative linkage is a disulfide bond.
The linkage reaction can be optimized for the particular cell-specific binding agent and gene-binding agent used to form the carrier. Reaction conditions can be designed to maximize linkage formation but to minimize the formation of aggregates of the carrier components. The optimal ratio of cell-specific binding agent to gene-binding agent can be determined empirically. When poly¬ cations are used, the molar ratio of the components will vary with the size of the polycation and the size of the gene. In general, this ratio ranges from about 10:1 to 1:1, preferably about 5:1. Uncoupled components and aggregates can be separated from the carrier by molecular sieve chromatography. The gene encoding the desired cell surface receptor can be complexed to the carrier by a stepwise dialysis procedure. In a preferred method, for use with carriers made of polycations such as polylysine, the dialysis procedure begins with a 2M NaCl dialyzate and ends with a 0.15M NaCl solution. The gradually decreasing NaCl concentration results in binding of the DNA to the carrier.
The molecular complex can contain more than one copy of the same gene or one or more different genes. Preferably, the ratio of polynucleotide to the carrier is from about 1:5 to 5:1, preferably about 1:2.
The molecular complex of this invention can be administered parenterally. Preferably, it is injected intravenously. The complex is administered in solution in a physiologically acceptable vehicle.
Cells can be transfected in vivo for transient expression and production of the gene product. For prolonged expression and production, the gene can be administered repeatedly. Alternatively, the transfected target cell can be stimulated to replicate by surgical or pharmacological means to prolong expression of the incorporated gene. See, for example, U.S. Patent Application Serial No. 588,013, filed September 25, 1990, the teachings of which are incorporated by reference herein.
The method of this invention can be used in gene therapy to selectively deliver a gene encoding a cell surface receptor to a target cell in vivo for expression. A gene encoding a desired cell surface receptor can be targeted to a cell which normally expresses the receptor but which lacks the capacity to produce the receptor or produces an insuffient amount of the receptor because of an acquired or inherited defect. For example, a normal gene can be targeted to a specific cell to correct or alleviate a metabolic or genetic abnormality caused by an inherited or acquired defect in a corresponding endogenous gene encoding a cell surface receptor. Alternatively, the gene can be delivered to a cell which does not normally express the surface receptor to confer a new function upon the cell.
The cell surface receptor can be a receptor for a natural ligand such as a metabolite, a hormone, a growth factor, a cytokine, an ion (ion transport protein), a virus, or a protozoan. It can also be a receptor that mediates cell-cell interaction.
In vivo gene transfer has several potential advantages over organ/cell transplantation in the treatment of metabolic diseases of the liver. One advantage is that the therapeutic gene is expressed in situ in a cell and organ that has not been manipulated ≤x vivo. In addition, the capacity of this approach to reconstitute hepatic gene expression is theoretically greater than the capacity of cellular therapies which are usually limited by the number of cells that will engraft. Finally, the therapeutic gene can be delivered to the appropriate cell in a noninvasive way with little apparent morbidity.
Familial hypercholesterolemia is an inherited disease in humans caused by a deficiency in the receptor for LDL. In a preferred embodiment, the gene encoding the human LDL receptor is complexed to a conjugate of an asialoglycoprotein and a polycation. The resulting soluble complex is administered parenterally to the individual afflicted with the LDL receptor deficiency in amounts sufficient to selectively transfect cells and to provide sufficient production of the cell surface receptor to attain normal levels of serum cholesterol. DNA encoding human LDL receptor is described in U.S. Patent 4,745,060, the contents of which are incorporated herein by reference.
This invention is illustrated further by the following Exemplification.
Exemplification
An asialoglycoprotein-polycation conjugate consisting of asialoorosomucoid (ASOR) coupled to polylysine, was used to form a soluble DNA complex capable of specifically targeting hepatocytes via asialoglycoprotein receptors present on these cells. The DNA comprised a plasmid, p9-12alb(h)LDLR, containing the structural gene for the human LDL receptor driven by rat albumin promoter and mouse albumin enhancer elements.
Animals
The efficacy of intravenous administration of the LDLR-complex was studied in an animal model of familial hypercholesterolimia, the Watanabe Heritable Hyperlipidemic (WHHL) rabbit. WHHL rabbits were derived from mating homozygous LDL-receptor deficient rabbits and were purchased from Dr. Mahlan at New York University. Wild-type New Zealand White (NZW) rabbits were purchased from Dutchland Farms (Denver, PA) . Animals were maintained on a Purina laboratory rabbit chow and weighed 2-3 kg at the time of experi¬ mentation. Phlebotomies were performed at 3 to 4 PM. Experiments were conducted in accordance with the guidelines of the Committee on Use and Care of Animals from the University of Michigan and Albert Einstein College of Medicine.
Construction of DNA Vector
A vector capable of expressing normal human LDL receptor was constructed (p9-12alb(h)LDLR) for in vivo gene transfer experiments in WHHL rabbits (Figure 1) . Transcriptional elements from the mouse albumin gene were used to drive expression of a full-length cDNA for the human LDL receptor. L.E. Babiss e± aj,. Proc. Natl. Acad. Sci. £1:6504 (1986); CA. Pinkert e± aj,. Genes Dev. 1:268 (1987); K.S. Zaret e±. aL. Proc. Natl. Acad. Sci. £5.:9076 (1988); and R.S. Herbat e_t si. Proc. Natl. Acad. Sci. ££:1553 (1989).
The expression vector was constructed in a single three-part ligation using fragments that were cloned in a directional manner (Figure 1) . The three fragments used in this construction are as follows: Fragment A is an Xbal to Bglll fragment (3.6 kb) of plasmid MTEV.JT (provided by J. Trill) which contains several functional elements including a 231 base pair (bp) fragment of genomic DNA spanning the polyadenyl- ation signal of the bovine growth hormone gene, β-lactamase and the prokaryotic origin of replication from PUC 19, and a eukaryotic transcriptional unit expressing xanthine-guanine phosphoribosyltransferase (XGPRT) ; Fragment B includes sequences spanning an enhancer located 5' to the mouse albumin gene (-12 to -9 kb) excised on an Eco RV to Bglll fragment and fused in reverse orientation to sequences spanning the mouse albumin promoter (-282 to +21). L.E. Babiss e_£ ≤l- Proc. Natl. Acad. Sci. £1:6504 (1986); CA. Pinkert e al . Genes Dev. 2:268 (1987); K.S. Zaret e_£ si- Proc. Natl. Acad. Sci. £5_:9076 (1988); and R.S. Herbat ej**. al. Proc. Natl. Acad. Sci. 86:1553
(1989). The 5' end of the chimeric fragment is formed by the natural Bglll site of the albumin enhancer (-9 kb) while the 3' end of the fragment contains a synthetic Sail site attached to position +22 of the albumin promoter sequence; and Fragment C is a Sail to Xbal fragment (3.0 kb) derived from a previously published retroviral vector LTR-LDLR. J.M. Wilson st al. Proc. Natl. Acad. Sci. ££:4421 (1988). The LTR-LDLR vector includes the entire cDNA for human LDL receptor (2.6 kb) along with 430 bp of additional 3' sequence derived from the retroviral genome (nucleotides 7816 to 8113 of the Moloney murine leukemia virus genome; see C. Van Beveren e_£ Si. in RNA Tumor Viruses (R. Weiss, N. Teich, H. Varmus, and J. Coffin eds.) Cold Spring Harbor Lab., Cold Spring Harbor N.Y., 2nd Ed., pp. 766-783 (1985) for numbering). The 5' end of the LDL receptor cDNA was converted to a Sail site in preparation for this construction. LDL receptor sequences in p9-12alb(h)LDLR were replaced with sequences encoding the prokaryotic gene chloroamphenicol acetyltransferase (CAT) to generate a vector called p9-12albCAT (provided by S. Camper). This vector was used as a negative control in metabolic experiments based on the assumption that CAT expression does not specifically affect intracellular hepatic cholesterol metabolism. DNA/protein complexes were synthesized with either p9-2alb(h)LDLR (LDLR-complex) or p9-12albCAT (CAT-complex) (See below) .
Construction of Gene Carrier and Gene Carrier Complexes
A high affinity ligand for the asialoglycoprotein receptor, asialoorosomucoid (ASOR) , was covalently attached to polylysine to produce a gene carrier useful in the study of the organ and cellular distribution of DNA/protein complex uptake in vivo. In order to introduce a radioisotope into the DNA/protein complex without perturbing its structural configuration LDLR- complexes were synthesized with
ASOR. The gene carriers were prepared as described previously. G.Y. Wu fit al. J. Biol. Chem. 2£4.:16985 (1989). Briefly, human orosomucoid isolated from pooled human plasma, was desialyted with neuraminidase and subsequently coupled to poly L-lysine (MW=59,000), using l-ethyl(-3-)-3-dimethyl amino propyl carbodiimide. The ASOR/poly L-lysine conjugate was purified by molecular sieve chromatography as described previously and complexed to plasmid DNA using an agarose gel retardation assay to determine optimal conjugate to DNA ratios for each plasmid. G.Y. Wu eJt al. J. Biol. Chem. ^£4:16985 (1989). Large scale complexes were made by successive stepwise dialysis of conjugate-DNA mixtures 18 hours each against 2 M, 1.5 M, 1.0 M, 0.5 M. and finally 0.2 M NaCl. Final samples were filtered through 0.45 μ membranes and checked by agarose gel electro- phoresis for the presence of protein/DNA complex and the absence of free DNA. ASOR was labeled with 125j (G.Y. Wu and CH. Wu J. Biol. Chem. 2£2:4429 (1987); and G.Y. Wu and CH. Wu Biochemistry .27:887 (1988)),
conjiagated to poly L-lysine, and the radiolabeled ASOR/poly L-lysine conjugate was complexed with p9-12alb(h)LDLR plasmid as described above.
Targeting of the LDLR-Complex to the Liver Animals were anesthetized with ketamine HC1 (40 mg/kg) and xylazine (10 mg/kg) in preparation for the experiment. Radiolabeled LDLR-complexes were injected into the marginal ear vein of New Zealand White (NZW) or WHHL adult rabbits (2 to 3 kg) which were euthenized and exanguinated 10 minutes later. Individual organs were harvested and analyzed for incorporation of radioactivity (Figure 2) . DNA/protein complex was rapidly cleared from the plasma and primarily taken up by the liver (85% of total recovered radioactivity) after 10 minutes. Organ distribution of uptake was shown to be independent of the phenotype of the recipient animal (NZW, heterozygous WHHL, and homozygous WHHL) and the dose of injected complex (from 0.17 mg to 4 mg of DNA in a complex) .
The average recovered radioactivity for the four animals presented in Figure 2 was estimated to be 99 +/-10 percent (mean +/- 1 S.D., N=4). Data are presented as % recovered radioactivity in individual organs including liver, spleen, lung, heart, kidney, and blood. (A) Tracer quantities of ASOR labeled complex (0.17 mg of DNA; specific activity = 2 x 106 cpm/μg) into a WHHL rabbit (homozygous). (B) Tracer quantities of ASOR labeled complex into a WHHL rabbit (heterozygous). (C) Tracer quantities of ASOR labeled complex (0.17 mg of DNA; specific activity = 2 x 106 cprn/μg) into a NZW rabbit. (D) Therapeutic
quantities of ASOR labeled complex (4.0 mg of DNA; specific activity = 0.85 x 105 cpm/μg) into a WHHL rabbit (homozygous) .
Cellular Distribution of the LDLR-Complex Although the hepatocyte is the predominant cell type in the liver and the likely target for gene transfer, nonparenchymal cells of the liver, such as endothelial cells and kupffer cells, could potential¬ ly serve as alternative targets. To visualize the cellular distribution of LDLR-complex, rabbits were injected with radiolabeled LDLR-complex as described above. Ten minutes after injection, the portal vein was cannulated, and the liver was perfused with 154 mM NaCl for 5 minutes followed by Karnovsky's fixative for 10 minutes. R. St. Hilaire fit al* Proc. Natl. Acad. Sci. 80:3797 (1983). Random blocks of liver were cut on ice to 2 - 5 mm^ cubes and were kept in fresh fixative for 2 hours prior to transfer to a 0.2 M sodium bicarbonate, pH 7.4, overnight at room temperature. Blocks were embedded in Epox 812 (W.O. Dobbins III in Diagnostic Electron Microscopy (B.F. Trump and R.T. Jones eds.) Wiley, New York, Vol. 1, pp. 253-339) and 1 μm sections were cut and mounted on polylysine-coated slides which were dipped in NTB3 nuclear emulsion. After exposure for 2 - 3 weeks at 4° C, slides were developed with Kodak D-19, and stained with 0.5% toluidine blue in 1% sodium benzoate (See Figure 3) . Panel A: Analysis of liver tissue from a WHHL that received ASOR labeled complex (4.0 mg of DNA; specific activity = 0.85 x 105 cprn/μg) . Panel B: Analysis of liver tissue from a WHHL rabbit that was injected with saline. In each case, magnification is 400x.
Radioactive signal, detected as silver grains, was 100-fold over that observed in unlabeled liver tissue (Figure 3). The majority of this signal (>90%) was seen as discrete grains located over hepatocytes (Figure 3A) . Radioactive signal was infrequently seen over kupffer cells as aggregates or discrete grains (Figure 3A) . This nonparenchymal cell uptake may represent larger forms of the DNA/protein complex that have been phagocytized by kupffer cells. These studies indicate that the DNA/protein complex is rapidly taken up by hepatocytes after injection into peripheral blood.
Intracellular Distribution of the LDLR-Complex
The intracellular fate of the recombinant gene was studied in WHHL rabbits after administration of unlabeled LDLR-complex. Animals were euthanized 10 minutes, 4 hours, and 24 hours after in vivo gene transfer and liver tissue was characterized with respect to the abundance and structural integrity of the recombinant gene as well as the level of recombinant derived RNA.
DNA Blot Hybridization Studies: Total cellular DNA isolated from liver of WHHL rabbits was analyzed for the presence of p9-12alb(h)LDLR DNA sequences by blot hybridization (Figure 4A) . J.M. Wilson fit al. Proc. Natl. Acad. Sci. £1:8437 (1990). DNA was restricted with Bam HI to excise a 1.4 kb fragment from the plasmid, fractionated by agarose gel electrophoresis, and transferred to Zetabind. Filters were hybridized with a vector specific restriction fragment (Hind III to Eco RI fragment of 3Z-env) that had been 32p
labeled to high specific activity. J.M. Wilson fit al. Proc. Natl. Acad. Sci. 85:4421 (1988). Samples include control WHHL DNA (10 μg) mixed with the equivalent of 100 copies/cell (750 pg; lane *100c'), 10 copies/cell (75 pg; lane '10c'), and 1 copy/cell (7.5 pg; lane ,lc') of p9-12alb(h)LDLR plasmid DNA. Additional DNA samples (10 μg) are from WHHL rabbits injected with LDLR-complex and harvested 10 minutes (lane '10 min'), 4 hours (lane '4 hr"), and 24 hours (lane *24 hr') later. The filter was exposed to film for 45 minutes (top panel) and 24 hours (bottom panel) . Molecular weight markers are noted in base pairs along the left border.
The results indicate that liver tissue harvested 10 minutes after injection of the LDLR-complex demonstrated very high levels of the intact fragment along with some partially degraded plasmid DNA; comparison to plasmid controls indicated that this tissue contained approximately 5,000 to 10,000 copies of plasmid per cell. This estimate of gene targeting is in agreement with the level of gene delivery to the liver expected from the amount of DNA injected (this estimate is based on the injection of 4 mg of plasmid (10 kb in size) into a 2-3 kg rabbit that has 2 - 4 x 1010 hepatocytes). Analysis of livers harvested at later time points revealed ongoing degradation of the plasmid and a progressive decline in the abundance of the intact plasmid from 100 copies/cell at 4 hours to 1 copy/cell at 24 hours. These experiments indicate that the LDLR-complex remains intact in the blood and capable of efficient delivery of large quantities of DNA to the liver. The internalized plasmid DNA is eventually degraded.
RNase Protection Assays:
Liver tissues were analyzed for the presence and abundance of recombinant human LDL receptor transcripts using a quantitative RNase protection assay. J.M. Wilson fit al. Proc. Natl. Acad. Sci.
£7:8437 (1990). RNA derived from the p9-12alb(h)LDLR vector was detected with an antisense RNA probe that is synthesized from the previously described vector 3Z-env. J.M. Wilson fit al. Proc. Natl. Acad. Sci. £7:8437 (1990). This RNA probe is complementary to vector specific sequences in the 3* untranslated region of the recombinant transcript. RNase protection of the resulting duplex produces a protected fragment of 172 bp (Figure 4B) . Antisense RNA that specifically detects endogenous WHHL LDL receptor RNA was used as an internal control in each assay.
The transcription vector used to synthesize the RNA probe (3Z-WLDLR) was constructed in the following manner. A restriction fragment from a WHHL LDL receptor cDNA clone, spanning the Sma I site at position 211 to the Nar I site at 514, was isolated (See T. Yamamoto fit al. Science 211:1230 (1986) for numbering) . The Nar I site was converted to a Hind III site with synthetic linkers and the revised fragment was ligated with the Hind III to Sma I backbone fragment of pGEM3Zf(+) (Promega). Endogenous WHHL LDL receptor RNA is detected with the 3Z-wLDLR probe in RNase protection assays as a 80 bp band. Transcription vectors were linearized with Eco RI (3Z-env) or Mnl I (3Z-wLDLR) and used as templates in transcription reactions according to the recommendations of the manufacturer (Promega). RNA
probes were gel purified prior to use. M.H. Finer in Methods in Molecular Biology. Vol. 7: Gene Transfer and Expression Techniques (E.J. Murray and J.M. Walker eds.) The Humana Press Inc., Clifton, NJ, pp. ι_i5 (1990).
Total cellular RNA prepared from liver was hybridized with equal quantities of 3Z-env and 3Z-wLDLR probe (5x10-5 cpm of each probe per assay) and analyzed for protection to digestion with RNase A. J.M. Wilson fit al. Proc. Natl. Acad. Sci. £7:8437 (1990). Samples were electrophoresed through a 6% polyacrylamide/urea denaturing gel; a representative autoradiograph is presented. Radioactivity in the resulting bands was quantified with a Beta Scope 630 (Betagen, Waltham MA) . The following samples were analyzed. Lane '3T3' contains RNA (100 μg) from a control WHHL supplemented with RNA (100 ng) from a fibroblast cell line (NIH3T3) that produces recombinant LDL receptor transcripts containing sequences complementary to the 3z-env probe.
Additional samples include RNA (100 μg) from an untransfected WHHL rabbit (lane 'Mock') and from WHHL rabbits injected with LDLR-complex and harvested 10 minutes (lane "10 min*), 4 hours (lane '4 hr'), and 24 hours (lanes 24A and 24B, representing two different animals) . The undigested probes (2 x 103 cpm/lane) were electrophoresed in lanes '3Z-env' and '3Z-WLDLR'. Molecular weight markers (γATP labeled pBr322/X Hae III fragments) and their corresponding sizes in base pairs are presented in the far right lane. The closed arrow indicates the location of the 3Z-env protected band while the open arrow indicates the location of the 3Z-wLDLR protected band.
Endogenous LDL receptor RNA was specifically detected in RNase protection assays as a 80 bp protected fragment; no hybridization to human LDL receptor RNA was noted. The intensity of the resulting bands is proportional to the amount of RNA used in the initial hybridization suggesting that this assay can be used to quantify recombinant and endogenous transcripts.
Recombinant RNA was not detected in mock-transfected liver or in liver harvested 10 minutes after administration of the LDLR-complex. Livers removed 4 hours and 24 hours after in vivo gene transfer contained significant levels of the recombinant transcript. Quantitative analysis of the assay was used to estimate the abundance of vector- derived RNA relative to the endogenous LDL receptor transcript; levels of the recombinant LDL receptor transcript rose from undetectable at 10 minutes (< 0.05% of endogenous), to 1.3% of endogenous at 4 hours, and 4.0% (24A) and 2.0% (24B) of endogenous at 24 hours.
Metabolic Effects of LDLR-Complex
Experiments were performed to determine the metabolic effects of hepatocyte directed gene transfer in vivo. WHHL rabbits were injected with LDLR-complex or CAT-complex and analyzed for changes in total serum cholesterol. Six WHHL rabbits were entered into a protocol that involved a two treatment (injection of p9-12alb(h)LDLR (LDLR-complex) or p9-12albCAT (CAT-complex) plasmid; 5.0 g of total DNA in a complex/dose), two period, cross-over design, with repeated measurements of total serum
cholesterol within each period (Figure 5). The DNA/protein complex was injected into the marginal ear vein over a 2 minute time period. Animals A-C received LDLR-complex on day 0 and CAT-complex on day 12, whereas animals D-F received CAT-complex on day 0 and LDLR complex on day 12. Venous samples were subsequently obtained through a marginal ear vein and analyzed for total serum cholesterol. P. Trinder Ann. Clin. Biochem. 12:226 (1974). The data were analyzed using a repeated measures analysis of covariance with the mean of the three baseline measurements as the covariate. B. Jones and M.G. Kenward Design and Analysis of Cross-Over Trials. Chapman and Hill, 1989. Injection of the LDLR-complex led to an immediate but transient decrease in total serum cholesterol by 25 to 30 % of the pretreatment value; this did not occur in animals injected with the CAT-complex. There was a statistically significant time trend on these differences (p<0.001) which reached a maximum value at two days after injection and then decreased thereafter, becoming non-significant following the sixth day after injection. No evidence of carry-over from one experiment to another was noted (p=0.8148). Areas under the cholesterol time curve were also analyzed. Treatment with LDLR-complex was associated with a highly significant decrease in the area under the cholesterol time curve (p=0.0035) compared to injection of the CAT-complex. There was no evidence of any carry-over (p=0.1625) or period effects (ρ=0.8010) .
Eguivalents
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the following claims.
Claims
1. A soluble molecular complex for targeting a gene encoding a cell surface receptor to a specific cell, the complex comprising an expressible gene encoding the cell surface receptor complexed with a carrier of a cell-specific binding agent and a gene-binding agent.
2. A soluble molecular complex of claim 1, wherein the expressible gene is DNA.
3. A soluble molecular complex of claim 1, wherein the expressible gene encodes the human LDL receptor.
4. A soluble molecular complex of claim 1, wherein the gene-binding agent is a polycation.
5. A soluble molecular complex of claim 4, wherein the polycation is polylysine.
6. A soluble molecular complex of claim 1, wherein the cell-specific binding agent binds a surface receptor of the cell which mediates endocytosis.
7. A soluble molecular complex of claim 6, wherein the cell-specific binding agent is a ligand for an asialoglycoprotein receptor.
8. A soluble molecular complex of claim 7, wherein the ligand is an asialoglycoprotein and the targeted cell is a hepatocyte.
9. A soluble molecular complex of claim 1, wherein the expressible gene is complexed with the gene-binding agent by a noncovalent bond.
10. A soluble molecular complex of claim 1, wherein the cell-specific binding agent is linked to the gene-binding agent by a covalent bond.
11. A soluble molecular complex of claim 1, wherein the expressible gene is complexed with the gene-binding agent so that the gene is released in functional form under intracellular conditions.
12. A pharmaceutical composition comprising a solution of the molecular complex of claim 1 and a physiologically acceptable vehicle.
13. A soluble molecular complex for targeting a gene encoding a cell surface receptor to a hepatocyte, the complex comprising an expressible gene encoding the cell surface receptor complexed with a carrier of a ligand for the asialoglycoprotein receptor and a polycation.
14. A soluble molecular complex of claim 13, wherein the expressible gene encodes the human LDL receptor.
15. A soluble molecular complex of claim 13, wherein the polycation is polylysine.
16. A soluble molecular complex of claim 13, wherein the gene is contained in an expression vector along with genetic regulatory elements necessary for expression of the gene by the hepatocyte.
17. A soluble molecular complex of claim 16, wherein the expression vector is a plasmid or viral DNA.
18. A soluble molecular complex for targeting a gene encoding the human LDL receptor to a hepatocyte, the complex comprising an expressible gene encoding the human LDL receptor complexed with a carrier of a ligand for the asialoglycoprotein receptor and a polycation.
19. A soluble molecular complex of claim 18, wherein the polycation is polylysine.
20. A method of delivering an expressible gene encoding a cell surface receptor to a specific cell of an organism for expression by the cell, comprising administering to the organism a soluble molecular complex comprising the expressible gene encoding the cell surface receptor complexed with a carrier of a cell-specific binding agent and a gene-binding agent.
21. A method of claim 20, wherein the expressible gene is DNA.
22. A method of claim 20, wherein the expressible gene encodes the human LDL receptor.
23. A method of claim 20, wherein the gene-binding agent is a polycation.
24. A method of claim 23, wherein the polycation is polylysine.
25. A method of claim 20, wherein the cell-specific binding agent binds a surface receptor of the cell which mediates endocytosis.
26. A method of claim 25, wherein the cell-specific binding agent is a ligand for an asialoglycoprotein receptor.
27. A method of claim 26, wherein the ligand is an asialoglycoprotein and the targeted cell is a hepatocyte.
28. A method of claim 20, wherein the molecular complex is administered intravenously.
29. A method of selectively transfecting hepatocytes in vivo with a gene encoding a cell surface receptor, comprising intravenously injecting a pharmaceutically acceptable solution of a molecular complex comprising an expression vector containing an expressible gene encoding the cell surface receptor complexed with a carrier of a ligand for the asialoglycoprotein receptor and a polycation.
30. A method of claim 29, wherein the expressible gene encodes the human LDL receptor.
31. A method of claim 29, wherein the polycation is polylysine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69559891A | 1991-05-03 | 1991-05-03 | |
US695,598 | 1991-05-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992019749A1 true WO1992019749A1 (en) | 1992-11-12 |
Family
ID=24793675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/003639 WO1992019749A1 (en) | 1991-05-03 | 1992-05-01 | Targeted delivery of genes encoding cell surface receptors |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU1922092A (en) |
WO (1) | WO1992019749A1 (en) |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993025673A1 (en) * | 1992-06-04 | 1993-12-23 | The Regents Of The University Of California | In vivo gene therapy with intron-free sequence of interest |
WO1995006723A1 (en) * | 1993-09-01 | 1995-03-09 | Boehringer Mannheim Gmbh | Method of marking eukaryotic cells by the use of a cell surface receptor as a marker |
WO1995025809A1 (en) * | 1994-03-23 | 1995-09-28 | Ohio University | Compacted nucleic acids and their delivery to cells |
US5521291A (en) * | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
US5547932A (en) * | 1991-09-30 | 1996-08-20 | Boehringer Ingelheim International Gmbh | Composition for introducing nucleic acid complexes into higher eucaryotic cells |
WO1996021036A3 (en) * | 1994-12-30 | 1996-09-06 | Viagene Inc | Nucleic acid condensing agents with reduced immunogenicity |
US5656609A (en) * | 1992-09-24 | 1997-08-12 | University Of Connecticut | Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine |
WO1997033998A1 (en) * | 1996-03-14 | 1997-09-18 | The Immune Response Corporation | Targeted delivery of genes encoding interferon |
US5728399A (en) * | 1994-06-29 | 1998-03-17 | University Of Conn. | Use of a bacterial component to enhance targeted delivery of polynucleotides to cells |
US5756353A (en) * | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
EP0773719A4 (en) * | 1994-07-29 | 1998-09-02 | Univ Emory | Compositions for targeting materials to cells containing androgen receptors |
US5844107A (en) * | 1994-03-23 | 1998-12-01 | Case Western Reserve University | Compacted nucleic acids and their delivery to cells |
US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US5889169A (en) * | 1991-05-16 | 1999-03-30 | Cold Spring Harbor Laboratory | Cell cycle regulatory protein p16 gene |
US5922859A (en) * | 1992-02-01 | 1999-07-13 | Boehringer Ingelheim International Gmbh | Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells |
US5962316A (en) * | 1992-10-16 | 1999-10-05 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
US5981273A (en) * | 1991-09-30 | 1999-11-09 | Boehringer Ingelheim Int'l. Gmbh | Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells |
US6001644A (en) * | 1991-12-17 | 1999-12-14 | The Regents Of The University Of California | Mammalian transformation complex comprising a lipid carrier and DNA encoding CFTR |
US6043030A (en) * | 1992-12-17 | 2000-03-28 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
US6077835A (en) * | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
US6083484A (en) * | 1996-10-17 | 2000-07-04 | Molecular Biosystems, Inc. | Microparticles stabilized by polynuclear chromium complexes and their use as ultrasound contrast agents |
US6162641A (en) * | 1997-06-06 | 2000-12-19 | The Regents Of The University Of Michigan | Neuregulin response element and uses therefor |
US6211334B1 (en) | 1992-10-16 | 2001-04-03 | Cold Spring Harbor | Cell-cycle regulatory proteins, and uses related thereto |
US6268214B1 (en) | 1996-04-04 | 2001-07-31 | Roche Diagnostics Gmbh | Vectors encoding a modified low affinity nerve growth factor receptor |
EP0833667A4 (en) * | 1995-06-07 | 2001-11-21 | Univ California | STABILIZATION OF POLYNUCLEOTIDE COMPLEXES |
EP0836645A4 (en) * | 1995-06-09 | 2001-11-21 | Univ California | Dry powder formulations of polynucleotide complexes |
US6331390B1 (en) | 1992-12-17 | 2001-12-18 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
WO2002079447A2 (en) | 2001-03-30 | 2002-10-10 | Avigenics, Inc. | Avian lysozyme promoter |
US6806084B1 (en) | 1992-06-04 | 2004-10-19 | The Regents Of The University Of California | Methods for compositions for in vivo gene delivery |
US6875588B2 (en) | 2001-11-30 | 2005-04-05 | Avigenics, Inc. | Ovomucoid promoter and methods of use |
WO2006081331A2 (en) | 2005-01-25 | 2006-08-03 | Prolexys Pharmaceuticals, Inc. | Quinoxaline derivatives as antitumor agents |
US7135562B2 (en) | 2002-03-14 | 2006-11-14 | University Of Cincinnati | Avian iFABP gene expression controlling region |
US7176300B2 (en) | 2001-03-30 | 2007-02-13 | Avigenics, Inc. | Avian lysozyme promoter |
US7255874B1 (en) | 2001-12-21 | 2007-08-14 | Closure Medical Corporation | Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto |
US7294507B2 (en) | 2001-11-30 | 2007-11-13 | Avigenics, Inc. | Ovomucoid promoters and methods of use |
US7323297B1 (en) | 1992-04-03 | 2008-01-29 | The Regents Of The University Of California | Stabilized polynucleotide complexes and methods |
US7335761B2 (en) | 2001-11-30 | 2008-02-26 | Avigenics, Inc. | Avian gene expression controlling regions |
US7541512B2 (en) | 2001-03-30 | 2009-06-02 | Synageva Biopharma Corp. | Avians containing a lysozyme promoter transgene |
US7550561B1 (en) | 1991-05-16 | 2009-06-23 | Cold Spring Harbor Laboratory | p16INK4 polypeptides |
US7550650B2 (en) | 2001-09-18 | 2009-06-23 | Synageva Biopharma Corp. | Production of a transgenic avian by cytoplasmic injection |
US7691632B2 (en) | 1993-11-18 | 2010-04-06 | Cold Spring Harbor Laboratory | Kit for detecting the level of cyclin-dependent kinase inhibitor P16 gene expression |
WO2010096388A2 (en) | 2009-02-18 | 2010-08-26 | Carnegie Mellon University | Quenched dendrimeric dyes for bright detection |
WO2011150079A1 (en) | 2010-05-25 | 2011-12-01 | Carnegie Mellon University | Targeted probes of cellular physiology |
EP2629094A1 (en) | 2007-01-24 | 2013-08-21 | Carnegie Mellon University | Optical biosensors |
EP3026432A2 (en) | 2010-12-27 | 2016-06-01 | Brown University | Method for predicting patient's response to biglycan treatment |
US9597346B2 (en) | 2010-01-15 | 2017-03-21 | Cornell University | Methods for reducing protein levels in a cell |
US10434177B2 (en) | 2014-11-17 | 2019-10-08 | Carnegie Mellon University | Activatable two-component photosensitizers |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2103064A1 (en) * | 1991-05-14 | 1992-11-15 | George Y. Wu | Targeted delivery of genes encoding immunogenic proteins |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989007136A2 (en) * | 1988-02-05 | 1989-08-10 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
-
1992
- 1992-05-01 AU AU19220/92A patent/AU1922092A/en not_active Abandoned
- 1992-05-01 WO PCT/US1992/003639 patent/WO1992019749A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989007136A2 (en) * | 1988-02-05 | 1989-08-10 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
Non-Patent Citations (5)
Title |
---|
BIOTHERAPY vol. 3, no. 1, January 1991, DORDRECHT, THE NETHERLANDS pages 87 - 95; G. WU ET AL.: 'Delivery systems for gene therapy.' * |
CLINICAL RESEARCH vol. 39, no. 2, 9 April 1991, THOROFARE NJ, US page 326A; M. GROSSMAN ET AL.: 'Hepatocyte-directed gene transfer in vivo leads to transient improvement of hypercholesterolemia in LDL receptor deficient rabbits.' * |
HEPATOLOGY vol. 12, no. 4(2), 1990, NEW YORK, US page 922; J. WILSON ET AL.: 'Targeted gene transfer to hepatocytes in vivo: Mechanism(s) of persistent gene expression.' * |
SOMATIC CELL AND MOLECULAR GENETICS vol. 17, no. 3, May 1991, NEW YORK pages 287 - 301; D. DICHEK ET AL.: 'Low-density-lipoprotein receptors in the Watanabe heritable hyperlipidemic rabbit.' * |
THE JOURNAL OF BIOLOGICAL CHEMISTRY vol. 267, no. 2, 15 January 1992, BALTIMORE MD, US pages 963 - 967; J. WILSON ET AL.: 'Hepatocyte-directed gene transfer in vivo leads to transient improvement of the hypercholesterolemia in low density lipoprotein receptor-deficient rabbits.' * |
Cited By (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7550561B1 (en) | 1991-05-16 | 2009-06-23 | Cold Spring Harbor Laboratory | p16INK4 polypeptides |
US5889169A (en) * | 1991-05-16 | 1999-03-30 | Cold Spring Harbor Laboratory | Cell cycle regulatory protein p16 gene |
US6274322B1 (en) * | 1991-09-30 | 2001-08-14 | Boehringer Ingelheim International Gmbh | Composition for introducing nucleic acid complexes into higher eucaryotic cells |
US6022735A (en) * | 1991-09-30 | 2000-02-08 | Boehringer Ingelheim International Gmbh | Composition for introducing nucleic acid complexes into higher eucaryotic cells |
US5981273A (en) * | 1991-09-30 | 1999-11-09 | Boehringer Ingelheim Int'l. Gmbh | Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells |
US5521291A (en) * | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
US5547932A (en) * | 1991-09-30 | 1996-08-20 | Boehringer Ingelheim International Gmbh | Composition for introducing nucleic acid complexes into higher eucaryotic cells |
US6001644A (en) * | 1991-12-17 | 1999-12-14 | The Regents Of The University Of California | Mammalian transformation complex comprising a lipid carrier and DNA encoding CFTR |
US6468798B1 (en) | 1991-12-17 | 2002-10-22 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol and liposome-based delivery |
US5756353A (en) * | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
US6620795B1 (en) | 1991-12-17 | 2003-09-16 | The Regents Of The University Of California | Mammalian transformation complex comprising a lipid carrier and DNA encoding CFTR |
US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US5922859A (en) * | 1992-02-01 | 1999-07-13 | Boehringer Ingelheim International Gmbh | Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells |
US7323297B1 (en) | 1992-04-03 | 2008-01-29 | The Regents Of The University Of California | Stabilized polynucleotide complexes and methods |
WO1993025673A1 (en) * | 1992-06-04 | 1993-12-23 | The Regents Of The University Of California | In vivo gene therapy with intron-free sequence of interest |
US5827703A (en) * | 1992-06-04 | 1998-10-27 | The Regents Of The University Of California | Methods and composition for in vivo gene therapy |
WO1993024640A3 (en) * | 1992-06-04 | 1994-04-28 | Univ California | Methods and compositions for in vivo gene therapy |
US6806084B1 (en) | 1992-06-04 | 2004-10-19 | The Regents Of The University Of California | Methods for compositions for in vivo gene delivery |
US5656609A (en) * | 1992-09-24 | 1997-08-12 | University Of Connecticut | Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine |
US5962316A (en) * | 1992-10-16 | 1999-10-05 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
US5968821A (en) * | 1992-10-16 | 1999-10-19 | Cold Spring Harbor Laboratories, Inc. | Cell-cycle regulatory proteins, and uses related thereto |
US6486131B2 (en) | 1992-10-16 | 2002-11-26 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
US6211334B1 (en) | 1992-10-16 | 2001-04-03 | Cold Spring Harbor | Cell-cycle regulatory proteins, and uses related thereto |
US7425617B2 (en) | 1992-10-16 | 2008-09-16 | Cold Spring Harbor Laboratory | Antibodies to the cell cycle regulatory protein p16 |
US6043030A (en) * | 1992-12-17 | 2000-03-28 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
US6331390B1 (en) | 1992-12-17 | 2001-12-18 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
WO1995006723A1 (en) * | 1993-09-01 | 1995-03-09 | Boehringer Mannheim Gmbh | Method of marking eukaryotic cells by the use of a cell surface receptor as a marker |
US6074836A (en) * | 1993-09-01 | 2000-06-13 | Boehringer Mannheim Gmbh | Method of marking eukaryotic cells |
US7691632B2 (en) | 1993-11-18 | 2010-04-06 | Cold Spring Harbor Laboratory | Kit for detecting the level of cyclin-dependent kinase inhibitor P16 gene expression |
US6077835A (en) * | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
US6008336A (en) * | 1994-03-23 | 1999-12-28 | Case Western Reserve University | Compacted nucleic acids and their delivery to cells |
US5877302A (en) * | 1994-03-23 | 1999-03-02 | Case Western Reserve University | Compacted nucleic acids and their delivery to cells |
US5844107A (en) * | 1994-03-23 | 1998-12-01 | Case Western Reserve University | Compacted nucleic acids and their delivery to cells |
WO1995025809A1 (en) * | 1994-03-23 | 1995-09-28 | Ohio University | Compacted nucleic acids and their delivery to cells |
US5728399A (en) * | 1994-06-29 | 1998-03-17 | University Of Conn. | Use of a bacterial component to enhance targeted delivery of polynucleotides to cells |
EP0773719A4 (en) * | 1994-07-29 | 1998-09-02 | Univ Emory | Compositions for targeting materials to cells containing androgen receptors |
WO1996021036A3 (en) * | 1994-12-30 | 1996-09-06 | Viagene Inc | Nucleic acid condensing agents with reduced immunogenicity |
EP0833667A4 (en) * | 1995-06-07 | 2001-11-21 | Univ California | STABILIZATION OF POLYNUCLEOTIDE COMPLEXES |
EP1491217A1 (en) * | 1995-06-07 | 2004-12-29 | The Regents Of The University Of California | Stabilization of polynucleotide complexes |
EP0836645A4 (en) * | 1995-06-09 | 2001-11-21 | Univ California | Dry powder formulations of polynucleotide complexes |
WO1997033998A1 (en) * | 1996-03-14 | 1997-09-18 | The Immune Response Corporation | Targeted delivery of genes encoding interferon |
US6331525B1 (en) | 1996-03-14 | 2001-12-18 | The Immune Response Corporation | Targeted delivery of genes encoding interferon |
US6069133A (en) * | 1996-03-14 | 2000-05-30 | The Immune Response Corporation | Targeted delivery of genes encoding interferon |
US6268214B1 (en) | 1996-04-04 | 2001-07-31 | Roche Diagnostics Gmbh | Vectors encoding a modified low affinity nerve growth factor receptor |
US6193953B1 (en) | 1996-10-17 | 2001-02-27 | Molecular Biosystems, Inc. | Stabilized microparticles and their use as ultrasound contrast agents |
US6083484A (en) * | 1996-10-17 | 2000-07-04 | Molecular Biosystems, Inc. | Microparticles stabilized by polynuclear chromium complexes and their use as ultrasound contrast agents |
US6162641A (en) * | 1997-06-06 | 2000-12-19 | The Regents Of The University Of Michigan | Neuregulin response element and uses therefor |
US7199279B2 (en) | 2001-03-30 | 2007-04-03 | Avigenics, Inc. | Recombinant promoters in avian cells |
US7176300B2 (en) | 2001-03-30 | 2007-02-13 | Avigenics, Inc. | Avian lysozyme promoter |
WO2002079447A2 (en) | 2001-03-30 | 2002-10-10 | Avigenics, Inc. | Avian lysozyme promoter |
US7541512B2 (en) | 2001-03-30 | 2009-06-02 | Synageva Biopharma Corp. | Avians containing a lysozyme promoter transgene |
US7550650B2 (en) | 2001-09-18 | 2009-06-23 | Synageva Biopharma Corp. | Production of a transgenic avian by cytoplasmic injection |
US7294507B2 (en) | 2001-11-30 | 2007-11-13 | Avigenics, Inc. | Ovomucoid promoters and methods of use |
US7335761B2 (en) | 2001-11-30 | 2008-02-26 | Avigenics, Inc. | Avian gene expression controlling regions |
US7375258B2 (en) | 2001-11-30 | 2008-05-20 | Avigenics, Inc. | Transgenic avians with an ovomucoid gene expression control region linked to a nucleotide sequence encoding a heterologous polypeptide |
US7812215B2 (en) | 2001-11-30 | 2010-10-12 | Synageva Biopharma Corp. | Methods and protein production using ovomucoid promoters |
US7507873B2 (en) | 2001-11-30 | 2009-03-24 | Avigenics, Inc. | Transgenic avians containing recombinant ovomucoid promoters |
US6875588B2 (en) | 2001-11-30 | 2005-04-05 | Avigenics, Inc. | Ovomucoid promoter and methods of use |
US7255874B1 (en) | 2001-12-21 | 2007-08-14 | Closure Medical Corporation | Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto |
US7135562B2 (en) | 2002-03-14 | 2006-11-14 | University Of Cincinnati | Avian iFABP gene expression controlling region |
WO2006081331A2 (en) | 2005-01-25 | 2006-08-03 | Prolexys Pharmaceuticals, Inc. | Quinoxaline derivatives as antitumor agents |
EP2629094A1 (en) | 2007-01-24 | 2013-08-21 | Carnegie Mellon University | Optical biosensors |
WO2010096388A2 (en) | 2009-02-18 | 2010-08-26 | Carnegie Mellon University | Quenched dendrimeric dyes for bright detection |
US9249306B2 (en) | 2009-02-18 | 2016-02-02 | Carnegie Mellon University | Quenched dendrimeric dyes for florescence detection |
US9597346B2 (en) | 2010-01-15 | 2017-03-21 | Cornell University | Methods for reducing protein levels in a cell |
WO2011150079A1 (en) | 2010-05-25 | 2011-12-01 | Carnegie Mellon University | Targeted probes of cellular physiology |
US9995679B2 (en) | 2010-05-25 | 2018-06-12 | Carnegie Mellon University | Targeted probes of cellular physiology |
EP3026432A2 (en) | 2010-12-27 | 2016-06-01 | Brown University | Method for predicting patient's response to biglycan treatment |
US10434177B2 (en) | 2014-11-17 | 2019-10-08 | Carnegie Mellon University | Activatable two-component photosensitizers |
US10946098B2 (en) | 2014-11-17 | 2021-03-16 | Carnegie Mellon University | Activatable two-component photosensitizers |
Also Published As
Publication number | Publication date |
---|---|
AU1922092A (en) | 1992-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1992019749A1 (en) | Targeted delivery of genes encoding cell surface receptors | |
Wilson et al. | Hepatocyte-directed gene transfer in vivo leads to transient improvement of hypercholesterolemia in low density lipoprotein receptor-deficient rabbits. | |
EP0587738B1 (en) | Targeted delivery of genes encoding secretory proteins | |
US6069133A (en) | Targeted delivery of genes encoding interferon | |
Guy et al. | Delivery of DNA into mammalian cells by receptor-mediated endocytosis and gene therapy | |
US5994316A (en) | Method of preparing polynucleotide-carrier complexes for delivery to cells | |
Wu et al. | Targeting genes: delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo | |
Perales et al. | An evaluation of receptor‐mediated gene transfer using synthetic DNA‐ligand complexes | |
Wu et al. | Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications | |
Kaneda et al. | Introduction and expression of the human insulin gene in adult rat liver | |
US6110490A (en) | Liposomal delivery system for biologically active agents | |
US6344436B1 (en) | Lipophilic peptides for macromolecule delivery | |
JP3056782B2 (en) | Pharmaceutical compositions for expression of genes in target organs | |
US6191257B1 (en) | Natural or recombinant DNA binding proteins as carriers for gene transfer or gene therapy | |
CA2134773A1 (en) | Methods and compositions for in vivo gene therapy | |
CA2126101A1 (en) | Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr) | |
JP2002517180A (en) | Novel vectors and genes exhibiting increased expression | |
JPH06503714A (en) | Long-term expression of polynucleotides introduced into cells | |
US5744326A (en) | Use of viral CIS-acting post-transcriptional regulatory sequences to increase expression of intronless genes containing near-consensus splice sites | |
CA2197770A1 (en) | Compositions for targeting materials to cells containing androgen receptors | |
Klink et al. | Gene therapy of cystic fibrosis (CF) airways: a review emphasizing targeting with lactose | |
CA2220708A1 (en) | Serum amyloid a protein | |
US6479464B1 (en) | Compositions and methods for highly efficient transfection | |
WO1998050078A1 (en) | Lipophilic and/or lytic peptides for specific delivery of nucleic acids to cells | |
AU735667B2 (en) | Targeted delivery of genes encoding secretory proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |